Overview
- Veradermics says it has secured financing and has begun multiple Phase 3 studies of VDPHL01, an extended‑release oral minoxidil for men and women.
- Two trials are enrolling men and a separate program marks the first Phase 3 study focused on female pattern hair loss.
- The company expects initial male Phase 3 data in the first half of 2026 and plans a New Drug Application submission in 2027, contingent on positive results.
- Phase 2 data reported average gains of 37.5 hairs/cm² at two months and 47.3 hairs/cm² at four months, with about 91% of participants noting visible improvement.
- The extended‑release design aims to sustain follicular exposure while avoiding bloodstream spikes seen with standard oral minoxidil, and no serious treatment‑related cardiac adverse events were reported in Phase 2.